Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Istituto Nazionale dei Tumori, Napoli, Italy

Survival: 6.5 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Gemzar
Country: Italy
City/State/Province: Napoli
Hospital: Istituto Nazionale dei Tumori
Journal: Link
Date: 3/2003

Patients: This Phase III trial involved 698 patients with advanced non-small-cell lung cancer. All patients were age 70 or older. Patients were divided into three groups. Group 1 comprised 233 patients. Group 2 comprised 233 patients. Group 3 comprised 232 patients.

Treatment: Patients in Group 1 were administered the drug vinorelbine. Patients in Group 2 were administered the drug gemcitabine. Patients in Group 3 were administered both drugs, vinorelbine and gemcitabine.

Toxicity: Grade 4 toxicities for patients in Group 2 included hematologic, cardiac, pulmonary, and hepatic. Other toxicities (grade 3 and below) included infection, bleeding, nausea/vomiting, diarrhea, mucositis, fatigue, skin, extravasation, fever, renal, constipation, central neurotoxicity, and peripheral neurotoxicity.

Results: Median survival for patients in Group 2 (gemcitabine) was 28 weeks (6.5 months).

Support: A number of the authors are associated with one or more pharmaceutical companies including AstraZeneca, Eli Lilly, Roche, Smith-Kline, Bristol-Myers Squibb, and Aventis.

Correspondence: Cesare Gridelli, MD

E-mail to a Friend Email Physician More Information